Yet another set of transvaginal mesh cases have been consolidated into an MDL, or multidistrict litigation, as the result of an order issued by a federal judicial panel at the beginning of August 2012. This latest transvaginal mesh MDL involves devices that were manufactured by Coloplast Corp.
The creation of the MDL means that all lawsuits in federal courts involving Coloplast transvaginal mesh will be consolidated before a single judge for the purposes of pre-trial issues such as discovery and motions. Then, each case will be transferred back to its original jurisdiction where the plaintiff will have the opportunity to try the case.
Currently, there are at least 65 lawsuits involving Coloplast mesh products that have been filed across the United States. These lawsuits allege defects in the design of transvaginal mesh products that are used to surgically repair pelvic organ prolapsed and stress urinary incontinence. Those defects, the plaintiffs allege, have led to pelvic pain, infections, protrusion of the mesh device, and a host of other complications.
The Coloplast MDL is only the latest in a string of federal cases related to transvaginal mesh products. Already in West Virginia (where these cases have been consolidated as well) there are four other MDLs involving C. R. Bard, Boston Scientific, Ethicon/Gynecare and American Medical System and their respective transvaginal mesh devices. A sixth MDL involving Mentor ObTape is before a Judge Land in The Middle District of Georgia.
@thumbnail.jpg)
A partner with Childers, Schlueter & Smith, LLC,, Brandon Smith has devoted his practice to pharmaceutical litigation, mass torts, products liability and serious personal injury. A frequent guest speaker at legal seminars all over the country—Brandon is focused on helping injured victims nationwide, however possible. Named a SuperLawyer again in 2019, he has also been called out as one of 10 Best Attorneys For Georgia by the American Institute Of Personal Injury Attorneys and a Top 100 Lawyer in Georgia by the National Trial Lawyers in 2019.
Comments for this article are closed.